

 Latest News

Why Peloton Stock Was Out of Breath on Friday
18 MINS AGO

TSX Ends Weak For 3rd Straight Day, But Gains 1.2% In Week
20 MINS AGO

Soccer-Late comeback gives Brentford 2-1 home win over Watford
36 MINS AGO



MARKET ACTIVITY 

NEWS + INSIGHTS 

SOLUTIONS 

ABOUT 

LOG IN

Strong Buy




5 Buy 0 Hold 0 Sell

Based on 5 analysts giving stock ratings to **Field Trip Health** in the past 3 months

\$12.39
▲ (285.98% Upside)

average price target is \$12.39 with a high forecast of \$19.78 and a low forecast of \$8.07. The average price target represents a 285.98% change from the last price of \$3.21



Highest Price Target \$19.78 | Average Price Target \$12.39 | Lowest Price Target \$8.07

Analyst Profile	Expert Firm	Price Target	Position	Upside / Downside	Action	Date	Follow	Article
Jason McCarthy ★★★★★	Maxim Group	\$11.00	BUY	242.68% Upside	Reiterated	17 Days Ago		
Patrick Trucchio ★★★★★	H.C. Wainwright	\$19.78	BUY	516.20% Upside	Reiterated	17 Days Ago		
Andrew Partheniou ★★★★★	Stifel Nicolaus	\$9.10	BUY	183.45% Upside	Reiterated	21 Days Ago		

COMPASS Pathways (CMPS)

Next up is COMPASS Pathways, a leader in psychedelic drug development. COMPASS is working on creating new treatments from psilocybin, the active ingredient in the so-called 'magic mushrooms.' COMPASS is working with psilocybin to create new therapies for treatment-resistant depression, a major issue in current mental health programs. Psilocybin's effects are similar to those produced by LSD or mescaline, and include a distorted perception, especially in the perception of time.

Psilocybin has been the subject of medical research since the 1960s, a track that picked up in the early 2000s. Three years ago, the US FDA granted Breakthrough Therapy Designation to COMPASS' psilocybin-assisted therapy for major depressive disorder and treatment-resistant depression, a move that put new life into the company's clinical research.

COMPASS has been releasing details on that research over the past several weeks. On November 9, the company announced positive top-line results from a 233-patient Phase IIb study of COMP360, its leading drug candidate. COMP360 is a psilocybin therapy for treatment-resistant depression, used as a single dose with psychological support. Patients in the study showed a 'rapid and sustained' response to treatment with a single dose. Clinically relevant reduction in depressive symptoms lasted as long as three weeks after dosing, with longer effect for higher doses up to 25mg.

Further data released earlier this month showed that the primary and secondary endpoints of the study confirm the topline results. Patients reported benefits beyond reduction of depression symptoms, and COMP360 was well tolerated. Results of this Phase IIb study, with an emphasis on determining proper dosage, will be used to plan a larger Phase III pivotal trial in 2022.

One important factor, however, differentiates COMPASS's treatment from other novel pharmaceuticals: psilocybin cannot be patented, as it is produced in large quantities in nature, by multiple species of mushrooms. Difficulties in protecting intellectual property will put an important headwind when COMPASS moves to commercialize the drug.

Even so, H.C. Wainwright's Trucchio is bullish here. The analyst notes a couple of factors that bode well for the program: "First, we believe the potential pivotal Phase 3 program could include the potential for flexible dosing, [and] could include the option for a second exploratory (active drug) session; we believe this could address variability of response among patients with TRD, who by definition are more difficult to treat. Secondly, clarity on the clinical development pathway should arrive in 1H22 following end-of-Phase 2 meetings with regulators including EMA (Europe) and FDA (U.S.), which so far have been open-minded in their approach to the clinical development of psilocybin, which we note has Breakthrough Therapy status in the U.S..."

To this end, Trucchio rates CMPS a Buy along with a \$120 price target. Investors could be pocketing gains of ~327%, should Trucchio's forecast hit the mark over the next 12 months. (To watch Trucchio's track record, [click here](#))

Overall, we're looking at a stock that has a unanimous Strong Buy consensus rating, despite its highly speculative nature; all 8 of the analysts who have reviewed this one recently agree that it's a Buy. The average price target of \$84.75 implies an upside of 201% by the end of next year. (See [CMPS stock forecast on TipRanks](#))

Strong Buy




8 Buy 0 Hold 0 Sell

Based on 8 analysts giving stock ratings to COMPASS Pathways in the past 3 months

\$84.75
▲ (201.39% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is \$84.75 with a high forecast of \$120.00 and a low forecast of \$65.00. The average price target represents a 201.39% change from the last price of \$28.12.



Highest Price Target **\$120.00** | Average Price Target **\$84.75** | Lowest Price Target **\$65.00**

Analyst Profile	Expert Firm	Price Target	Position	Upside / Downside	Action	Date	Follow	Article
Patrick Trucchio ★★★★★	H.C. Wainwright	\$120.00	BUY	326.74% Upside	Reiterated	17 Days Ago		
Esther Hong ★★★★★	Berenberg Bank	\$84.00	BUY	198.72% Upside	Reiterated	24 Days Ago		
Jason McCarthy ★★★★★	Maxim Group	\$70.00	BUY	148.93% Upside	Reiterated	29 Days Ago		

To find good ideas for stocks trading at attractive valuations, visit TipRanks' [Best Stocks to Buy](#), a newly launched tool that unites all of TipRanks' equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

TRENDING TOPICS

Markets

Stocks

US Markets

Personal Finance

TRENDING ARTICLES

Nubank (NU Stock) IPO: Here's What Investors Need To Know

2 DAYS AGO

7 Best Cryptos to Buy Before 2022 If You Dream of Getting Rich

NOV 16, 2021

EXCLUSIVE-IMF, 10 countries simulate cyber attack on global financial system

1 DAY AGO

1 DAY AGO

All-new World Reimagined podcast

[Listen Now](#)

IN THIS STORY

[CMPS](#) [FTRP](#)

Latest Markets Videos

NOW
PLAYING

Examining How Markets Have Reached A Crossroads At The Start Of 2022
DEC 10, 2021

Volatility Trends And Outlook Into The New Year
DEC 10, 2021

The Week's Top Stories: Crypto, Roku & Hong Kong Exod
DEC 10, 2021

The Backdrop Of Covid, Interest Rates, And Inflation. #2022outlook
DEC 09, 2021

SEE MORE VIDEOS [→](#)

All-new World Reimagined podcast

[Listen Now](#)

TipRanks



TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.

[LEARN MORE](#) [→](#)



Explore Markets

EXPLORE 

Most Popular

01

Morgan Stanley Pounds the Table on NIO Stock
DEC 2, 2021

02

RSI Alert: NIO Now Oversold
DEC 3, 2021

03

Hackers Steal \$200M Worth Of Shiba Inu, Saitama, And Other Tokens From Bitmart Exchange
5 DAYS AGO

04

Burger King Launching 'Royal Perks' Loyalty Program Nationwide
SEP 3, 2021

Market Makers

Sign up for our newsletter to get the latest on the transformative forces shaping the global economy, delivered every Thursday.

All Text Fields Are Required

example@yourdomain.com

United States

SUBMIT

[INVESTOR RELATIONS](#)

[CONTACT](#)

[CAREERS](#)

[ADVERTISE](#)

[MOBILE APPS](#)

[NASDAQ MARKETSITE](#)

[TRUST CENTER](#)

[NEWSLETTERS](#)

[PRIVACY POLICY](#)

[COOKIES](#)

[LEGAL](#)

[DO NOT SELL MY PERSONAL INFORMATION \(CA RESIDENTS ONLY\)](#)



© 2021, Nasdaq, Inc. All Rights Reserved.

MY QUOTES

